Green Tea (EGCG) for Cancer Prevention: What the Japanese Cohort Studies Show

The Bottom Line

Epigallocatechin gallate (EGCG) is the primary bioactive polyphenol in green tea, responsible for the cancer prevention signal seen in large Japanese cohort studies. It inhibits VEGF (anti-angiogenic), EGFR, NF-kB, and multiple kinases. Phase II data exists in prostate cancer showing PSA stabilization. A meta-analysis of green tea consumption found 20-30% reduced risk of several cancer types among high consumers. The evidence supports green tea as a cancer prevention beverage, though the supplement evidence is less clear.

The Epidemiological Evidence

Japan Collaborative Cohort Study: Women drinking 5+ cups/day had significantly lower cancer mortality
Shanghai Women's Health Study: Regular green tea consumption associated with reduced colorectal cancer risk
Meta-analyses: High green tea consumption associated with 20-30% reduced risk of breast, prostate, and colorectal cancers. Dose-response relationship: more tea = more protection
Caveat: These are observational studies. Green tea drinkers may have healthier lifestyles overall. But the consistency across populations and the mechanistic plausibility strengthen the case.

How EGCG Works Against Cancer

VEGF inhibition: Blocks new blood vessel growth that tumors need. Anti-angiogenic at achievable concentrations.
EGFR inhibition: Blocks epidermal growth factor receptor, a key driver in many cancers (targeted by drugs like erlotinib)
NF-kB suppression: Reduces inflammatory signaling
Epigenetic effects: DNMT inhibition, potentially reactivating tumor suppressor genes
Proteasome inhibition: At high concentrations, EGCG inhibits the 20S proteasome (same target as bortezomib, an approved cancer drug)
Apoptosis induction: Activates caspase pathways in cancer cells

Human Clinical Data

Prostate cancer (Bettuzzi et al., 2006): RCT in men with high-grade prostatic intraepithelial neoplasia. Green tea catechins (600mg/day) reduced progression to prostate cancer from 30% to 3% over one year. Small study (60 patients) but striking result.
Breast cancer: Phase I studies established safety of EGCG supplements. Epidemiological association but no definitive prevention trial.
Colorectal adenoma recurrence: Japanese trial showed green tea extract reduced adenoma recurrence by ~50% over 3 years.

Green Tea vs. EGCG Supplements

1 cup of green tea: ~50-100mg catechins, of which 25-50mg is EGCG
5 cups/day: ~250-500mg catechins (the epidemiologically protective dose)
Supplements: Typically 400-800mg EGCG per capsule
Safety note: High-dose EGCG supplements have been linked to rare cases of liver toxicity. Drinking green tea has not. The extract concentrates EGCG beyond what food provides.
Our preference: Drink 3-5 cups of quality green tea daily. Supplements are an option but choose ones with liver safety data and don't exceed 800mg EGCG/day.

Practical Protocol

Beverage: 3-5 cups of quality loose-leaf green tea daily (matcha is highest in EGCG)
Supplement: 400-800mg EGCG daily if not a tea drinker
Timing: Between meals (tannins can reduce iron absorption)
Safety: Safe as tea. Supplements: monitor liver function if taking >800mg EGCG. Avoid on empty stomach.
Cost: $10-20/month (tea) or $15-25/month (supplements)

Our Assessment

Green tea/EGCG has one of the strongest cases for cancer prevention from a dietary source. The epidemiological data is consistent, the mechanism is multi-target and well-characterized, and small clinical trials show signals in prostate and colorectal cancer. As a beverage, the risk-benefit ratio is outstanding. As a supplement, it's promising but monitor liver function at high doses. Green tea should be part of a cancer prevention lifestyle alongside exercise, cruciferous vegetables, and adequate vitamin D.

Sources

Bettuzzi S, et al. Cancer Research 2006: Green tea catechins and prostate cancer prevention
Shimizu M, et al. Cancer Prevention Research 2008: Green tea extract and colorectal adenomas
PMC: Comprehensive review of EGCG anticancer mechanisms
Japan Collaborative Cohort Study: Green tea and cancer mortality